News & Events

Oct 4 2021

Orasis Pharmaceuticals Appoints Julie Speed as Senior Vice President, Head of Strategy and Marketing to Lead Commercial Growth Plan

Apr 26 2021

Orasis Pharmaceuticals Appoints Industry Veteran, Paul Smith, as President and Chief Operating Officer to Lead the Next Phase of Growth

Oct 28 2020

Orasis Pharmaceuticals Announces Initiation of Phase 3 Clinical Studies of Novel Eye Drop Candidate for the Treatment of Presbyopia

Sep 10 2020

Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopia

Oct 10 2019

Orasis Pharmaceuticals Announces CSF-1 Eye Drop Successfully Met Primary Endpoint in Phase 2b Clinical Study in Presbyopia

Mar 27 2019

Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopia

Nov 27 2018

Orasis Announces Appointments of Richard L. Lindstrom, Eric D. Donnenfeld, and John Berdahl to its Scientific Advisory Board

Oct 22 2018

Orasis Announces the Appointment of Jeffry Weinhuff as Chairman of the Board of Directors

June 5 2018

Orasis Pharmaceuticals Closes $13 Million Series B Financing

In the News

Dec 16 2020

In this Optical Journal Podcast episode, Orasis Pharmaceuticals CEO Elad Kedar is featured discussing presbyopia, the company’s Phase 3 U.S. clinical studies, and future plans for its novel eye drop candidate.

Dec 8 2020

Our CEO Elad Kedar joins the Eye On Vision radio show in this episode to talk about the unmet need for presbyopia treatments where reading glasses, the current standard of care, carry the stigma of aging. Also learn more about the company’s Phase 3 U.S. clinical studies of its novel eye drop candidate.

Nov 30 2020

Orasis Pharmaceuticals’ recently initiated Phase 3 U.S. clinical trials are covered by Eyewire News TV, INVISION Magazine, Healio Ocular Surgery News, OPTIK and Ophthalmology Web. Learn more about our plans to further evaluate the efficacy and safety of our eye drop candidate.

Sep 11 2020

This Healio article shares how funds from Orasis’ recent $30M Series C financing will be used to advance our eye drop candidate for the treatment of presbyopia symptoms through Phase 3 clinical trials and pre-commercialization activities.

Sep 11 2020

This FierceBiotech article discusses the company’s $30M raise that will fuel capitalization for Phase 3 clinical trials and an initial growth strategy for commercialization.

Sep 11 2020

Chief executive officer Elad Kedar spoke with BioSpace on the company’s recent Series C financing and how the funding will be used to propel Orasis’ lead asset for the treatment of presbyopia symptoms into Phase 3 clinical trials.

Sep 10 2020

This FINSMES article discusses our raise of $30M in a Series C funding. Find out more about the financing and how we are committed to making near vision clear again for people with presbyopia.

Sep 10 2020

Globes reported on our recent Series C financing, highlighting presbyopia prevalence, lead investors and how Orasis is looking to use the funds for pre-commercialization activities as well as Phase 3 clinical trials.

Sep 10 2020

Our chief executive officer Elad Kedar discusses in this Endpoints feature how Orasis with the recently completed $30M Series C financing plan to advance its pre-commercialization activities and Phase 3 clinical studies. The full story gives additional information on our novel treatment in development for presbyopia symptoms.

May 11 2020

Chief executive officer Elad Kedar spoke with the OIS Podcast on his strategy for success in completing a Phase 2b clinical study and how Orasis is now preparing to move into Phase 3 with our product candidate CSF-1. Chairman Jeffry Weinhuff also offers insights into Visionary Ventures’ investment decisions. Listen to the full podcast here.

Jan 28 2020

Chief executive officer, Elad Kedar, spoke with the Bio Report podcast on the potential of CSF-1 to treat presbyopia or age-related farsightedness and the eye drop’s recent positive Phase 2b study results. Listen to the full podcast here.

Nov 14 2019

Following the positive results from our Phase 2b U.S. clinical trial of CSF-1, Orasis CEO Elad Kedar spoke with Healio Ocular Surgery News about the eye drop and its potential as a meaningful treatment for people with presbyopia. Watch the full interview

May 29 2019

Orasis CEO Elad Kedar was interviewed by Ophthalmology Innovation Summit (OIS) TV about our corrective eye drop for the treatment of presbyopia and progress in our Phase 2b clinical study

Apr 8 2019

CEO Elad Kedar Discusses Our Ongoing Phase 2b Clinical Study of CSF-1 and the Eye Drop’s Treatment Effect with Healio

Dec 6 2018

Elad Kedar Featured on the Empowered Patient Podcast

Oct 25 2018

Orasis CEO Elad Kedar Discusses CSF-1 with EyeWorld at the 2018 Ophthalmology Innovation Summit during the Annual AAO Conference

Oct 22 2018

Orasis Announces the Appointment of Jeffry Weinhuff as Chairman of the Board of Directors

Jun 8 2018

Orasis Completes Financing for Development of Drop to Treat Presbyopia

Jun 6 2018

Orasis Raises $13 Million to Replace Reading Glasses with Eye Drops

Jun 6 2018

Farsighted Treatment Co Orasis Pharmaceuticals Raises $13M

Jun 5 2018

Orasis Pharmaceuticals Closes $13M Series B Financing